For over 25 years, the HHS Office of Inspector General has conducted work to assess drug spending in HHS programs. This work covers three domains: reimbursement, program compliance, and incentive alignment. This page is a compilation of completed reports, unimplemented recommendations, enforcement actions, and industry guidance.
OIG's portfolio on drug spending focuses on the following areas:
OIG work examining the financial impact of drug reimbursement and rebate policies on Federal spending.
OIG work examining whether drug manufacturers, State Medicaid agencies, and other entities are complying with statutory and program requirements.
OIG work exploring situations in which entities involved with HHS programs may have incentives not aligned with HHS program goals, adversely affecting those programs and their beneficiaries.